Comparison
3 Methylglutaconic Aciduria C3696376 vs 3mc Syndrome 2 C0796279
Clinical comparison between 3 Methylglutaconic Aciduria and 3mc Syndrome 2 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria C3696376
A metabolic disorder causing abnormal acid buildup affecting multiple body systems including the brain. Severity varies widely among affected individuals. Care focuses on symptom management and metabolic support.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
3 Methylglutaconic Aciduria C3696376
0-10
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria C3696376
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria C3696376
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria C3696376
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
3 Methylglutaconic Aciduria C3696376
metabolic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
3 Methylglutaconic Aciduria C3696376
metabolic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-C3696376 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria C3696376 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Metabolic acid findings | Described as abnormal acid buildup that can involve multiple systems, including the brain. | Not described as an organic aciduria; features are congenital and multisystem. | High |
| Facial and growth pattern | No characteristic facial or growth pattern is established in the supplied description. | Facial, developmental, and growth manifestations are the stated features. | Moderate |
| Timing of recognition | Supplied onset range is childhood, from birth through age 10. | Supplied onset is at birth, consistent with a congenital condition. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria C3696376 when
Suspected inborn error with acid accumulation
The source places this concept in a metabolic category with abnormal acid buildup.
Moderate
Neurologic concerns alongside metabolic illness
Brain involvement is mentioned, although specific symptoms are not established.
Low
Planning metabolic supportive care
Described care emphasizes symptom management and metabolic support.
Moderate
Choose 3mc Syndrome 2 C0796279 when
Congenital features present from birth
The supplied onset and congenital classification support this direction.
Moderate
Facial, developmental, or growth concerns
These manifestations are explicitly described for 3MC syndrome 2.
Moderate
Genetic syndrome evaluation without aciduria
The source categorizes it as genetic and congenital rather than metabolic.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria C3696376 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May be relevant when abnormal organic acids are suspected; exact cutoff not supplied. | No defining organic-acid abnormality is established in the source. | An abnormal metabolite result is not itself a diagnosis and needs clinician review. |
| Genetic testing | May be considered after a persistent metabolic phenotype is assessed. | May be considered when congenital syndrome features suggest 3MC syndrome 2. | Gene selection and interpretation depend on phenotype; results are not definitive alone. |
| Clinical dysmorphology and development review | Neurologic findings may occur, but a specific pattern is not established. | Facial, growth, and developmental assessment is central to evaluation. | Examination guides referral; no single finding here confirms either condition. |
Prognosis comparison
3 Methylglutaconic Aciduria C3696376
- Outcome
- Course is chronic and severity varies widely; exact outcome is not established.
- Factors
- Metabolic stability, neurologic involvement, and access to supportive care may influence course.
3mc Syndrome 2 C0796279
- Outcome
- Course is chronic and congenital; precise prognosis is not established.
- Factors
- Developmental needs, growth issues, and associated anomalies may influence support needs.
Time frame: Lifelong, with individual variation.
Phenotype, complications, coordinated specialist care, and family support; no mortality estimate is supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic or developmental impact | Brain involvement is described, with widely variable severity. Developmental manifestations are described, without a quantified range. Frequency and severity are not established by the supplied data. |
| Metabolic decompensation | Acid buildup makes metabolic instability a possible concern. Not described as a primary metabolic-crisis disorder. Triggers and emergency thresholds are not provided and require individual planning. |
| Growth difficulty | Growth effects are not specifically established in the source. Growth manifestations are part of the stated congenital picture. Supportive management should be individualized; no treatment dose is implied. |
Patient education highlights
- HighDifferent conditions
Similar names do not mean the same disease; one is metabolic and the other congenital-genetic.
- HighTest versus diagnosis
An abnormal laboratory result needs confirmation and does not by itself establish either diagnosis.
- MediumWhen to seek care
New neurologic change, poor feeding, or acute illness should be assessed urgently by a clinician.